Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
October 18, 2024 06:47 ET
|
Novartis Pharma AG
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment...
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
October 17, 2024 09:15 ET
|
Renovaro Inc
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the...
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
October 15, 2024 14:30 ET
|
Tevogen Bio Inc
Approximately one in three women remain HPV positive after cervical procedures for precancerous lesions.Tens of thousands of women in the US each year are diagnosed with high-grade cervical...
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use
October 15, 2024 11:36 ET
|
Tevogen Bio Inc
Tevogen Bio CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
October 15, 2024 09:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics and Flatiron Health partner to make genetic testing more accessible with EMR integration
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
October 14, 2024 18:43 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID
October 11, 2024 12:12 ET
|
Tevogen Bio Inc
Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Expanding its pipeline to include non-oncology products, an opportunistic...
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 10, 2024 07:30 ET
|
Purple Biotech Ltd.
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer ...
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
October 10, 2024 04:15 ET
|
ICPO Foundation
The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for...